dr. R.H. Enting

E-mail:
r.h.enting umcg.nl

Research

  1. 2019
  2. 2018
  3. Gao, Y., Weenink, B., van den Bent, M. J., Erdem-Eraslan, L., Kros, J. M., Smitt, P. A. E. S., ... French, P. J. (2018). Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. European Journal of Cancer, 94, 168-178. https://doi.org/10.1016/j.ejca.2018.02.023
  4. Bady, P., Kurscheid, S., Delorenzi, M., Gorlia, T., van den Bent, M. J., Hoang-Xuan, K., ... Hegi, M. E. (2018). The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathologica, 135(4), 601-615. https://doi.org/10.1007/s00401-018-1810-6
  5. 2017
  6. van Linde, M. E., Brahm, C. G., Hamer, P. C. D. W., Reijneveld, J. C., Bruynzeel, A. M. E., Vandertop, W. P., ... Verheul, H. M. W. (2017). Treatment outcome of patients with recurrent glioblastoma multiforme: A retrospective multicenter analysis. JOURNAL OF NEURO-ONCOLOGY, 135(1), 183-192. https://doi.org/10.1007/s11060-017-2564-z
  7. 2016
  8. Reijneveld, J. C., Taphoorn, M. J. B., Coens, C., Bromberg, J. E. C., Mason, W. P., Hoang-Xuan, K., ... Baumert, B. G. (2016). Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, 17(11), 1533-1542. https://doi.org/10.1016/S1470-2045(16)30305-9
  9. Baumert, B. G., Hegi, M. E., van den Bent, M. J., von Deimling, A., Gorlia, T., Hoang-Xuan, K., ... Stupp, R. (2016). Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncology, 17(11), 1521-1532. https://doi.org/10.1016/S1470-2045(16)30313-8
  10. van Sonderen, A., Schreurs, M. W. J., de Bruijn, M. A. A. M., Boukhrissi, S., Nagtzaam, M. M. P., Hulsenboom, E. S. P., ... Titulaer, M. J. (2016). The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies. Neurology, 86(18), 1692-1699. https://doi.org/10.1212/WNL.0000000000002637
  11. 2015
  12. 2014
  13. Ho, V. K. Y., Reijneveld, J. C., Enting, R., Bienfait, H. P., Robe, P., Baumert, B. G., ... Dutch Soc Neuro-Oncology LWNO (2014). Changing incidence and improved survival of gliomas. European Journal of Cancer, 50(13), 2309-2318. https://doi.org/10.1016/j.ejca.2014.05.019
  14. Habets, E. J. J., Taphoorn, M. J. B., Nederend, S., Klein, M., Delgadillo, D., Hoang-Xuan, K., ... Reijneveld, J. C. (2014). Health-related quality of life and cognitive functioning in longterm anaplastic oligodendroglioma and oligoastrocytoma survivors. JOURNAL OF NEURO-ONCOLOGY, 116(1), 161-168. https://doi.org/10.1007/s11060-013-1278-0
  15. 2013
  16. 2012
  17. 2011
  18. 2010
  19. Schuurmans, M., Bromberg, J. E. C., Doorduijn, J., Poortmans, P., Taphoorn, M. J. B., Seute, T., ... van den Bent, M. J. (2010). Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis. British Journal of Haematology, 151(2), 179-184. https://doi.org/10.1111/j.1365-2141.2010.08328.x
  20. 2009
  21. Gehring, K., Sitskoorn, M. M., Gundy, C. M., Sikkes, S. A. M., Klein, M., Postma, T. J., ... Aaronson, N. K. (2009). Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. Journal of Clinical Oncology, 27(22), 3712-3722. https://doi.org/10.1200/JCO.2008.20.5765
  22. 2008
  23. 2007
  24. Sillevis Smitt, P. A. E., Polman, S. K. L., de Beukelaar, J. W. K., Enting, R. H., van den Bent, M. J., Bromberg, J. E., ... Hooijkaas, H. (2007). Drie patiënten met een paraneoplastisch neurologisch syndroom; de betekenis van paraneoplastische antistoffen. Nederlands Tijdschrift voor Geneeskunde, 151(15), 874-880.
  25. 2006
  26. 2005
  27. Taal, W., van der Rijt, C. D. D., Sillevis Smitt, P. A. E., Kros, J. M., van Heuvel, I., Enting, R. H., & van den Bent, M. J. (2005). Gunstig resultaat van temozolomide bij een recidiefvan een hooggradig glioom. Nederlands Tijdschrift voor Geneeskunde, 149(25), 1393-1399.
  28. Stege, E. M. B., Kros, J. M., de Bruin, H. G., Enting, R. H., van Heuvel, I., Looijenga, L. H. J., ... van den Bent, M. J. (2005). Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer, 103(4), 802-809. https://doi.org/10.1002/cncr.20828
  29. Enting, R., Mucchiano, C., Oldenmenger, WH., Fritzon, M., Wallen, A., Goslinga-van der Gaag, S., ... Delhaas, E. (2005). The "pain pen" for breakthrough cancer pain: A promising treatment. Journal of Pain and Symptom Management, 29(2), 213-217. https://doi.org/10.1016/j.jpainsymman.2004.05.010
  30. 2004
  31. Triebels, V. H. J. M., Taphoorn, M. J. B., Brandes, A. A., Menten, J., Frenay, M., Tosoni, A., ... van den Bent, M. J. (2004). Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology, 63(5), 904-906. https://doi.org/10.​1212/​01.​WNL.​0000137049.​65631.​DB
  32. ten Tije, A. J., Loos, W. J., Zhao, M., Baker, S. D., Enting, R. H., van der Meulen, H., ... Sparreboom, A. (2004). Limited cerebrospinal fluid penetration of docetaxel. Anti-Cancer Drugs, 15(7), 715-718.
  33. 2002
  34. Enting, R. H., Oldenmenger, W. H., van der Rijt, C. C. D., Wilms, E. B., Elfrink, E. J., Elswijk, I., & Sillevis Smitt, P. A. E. (2002). A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Cancer, 94(11), 3049-3056. https://doi.org/10.1002/cncr.10518
  35. Enting, R. H., Oldenmenger, W. H., van der Rijt, C. CD., Koper, P., Lieverse, P. J., & Smitt Sillevis, P. AE. (2002). Nitrous oxide is not beneficial for breakthrough cancer pain. Palliative Medicine, 16(3), 257-259. https://doi.org/10.1191/0269216302pm546xx
  36. 2001
  37. Enting, R. H., van der Rijt, C. C., Wilms, E. B., Lieverse, P. J., de Wit, R., & Smitt, P. A. (2001). Behandeling van pijn bij kanker met systemisch toegediende opioïden. Nederlands Tijdschrift voor Geneeskunde, 145(20), 950-954.
  38. 2000
  39. Gisolf, E. H., Enting, R. H., Jurriaans, S., de Wolf, F., van der Ende, M. E., Hoetelmans, R. M., ... Danner, S. A. (2000). Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine. Aids, 14(11), 1583-9.
Previous 1 2 Next

ID: 17564626